Biodexa Pharmaceuticals PLC announced a change in the ratio of its American Depositary Shares (ADSs) from one ADS representing fifty ordinary shares to one ADS representing four hundred ordinary shares. This adjustment is equivalent to a one-for-eight reverse ADS split for ADS holders, who must surrender eight old ADSs for cancellation and exchange for one new ADS. The effective date is expected on or about October 26, 2026. No fractional ADSs will be allocated; aggregate fractions will be sold with net proceeds distributed to entitled holders. The company's ordinary shares are not affected by this change. Biodexa Pharmaceuticals PLC operates in the biopharmaceutical industry, focusing on the development of drug candidates for inflammatory and immune-mediated diseases.
